TNF and syringocystadenoma papilliferum: Similar results to those obtained with OSCSCs were also observed when undifferentiated or stem-like Mia-Paca-2 (MP2) pancreatic tumors or SCAP were used to treat with the supernatants of NK cells treated with IL-2 + anti-CD16 mAb in the presence and absence of anti-TNF-α and/or anti-IFN-γ (Figure S1 in Supplementary Material).